GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Longevity Health Holdings Inc (NAS:XAGE) » Definitions » Gross Profit

XAGE (Longevity Health Holdings) Gross Profit : $0.04 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Longevity Health Holdings Gross Profit?

Longevity Health Holdings's gross profit for the three months ended in Dec. 2024 was $0.02 Mil. Longevity Health Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.04 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Longevity Health Holdings's gross profit for the three months ended in Dec. 2024 was $0.02 Mil. Longevity Health Holdings's Revenue for the three months ended in Dec. 2024 was $0.02 Mil. Therefore, Longevity Health Holdings's Gross Margin % for the quarter that ended in Dec. 2024 was 94.12%.

Longevity Health Holdings had a gross margin of 94.12% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 4 years, the highest Gross Margin % of Longevity Health Holdings was 88.00%. The lowest was 88.00%. And the median was 88.00%.


Longevity Health Holdings Gross Profit Historical Data

The historical data trend for Longevity Health Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Health Holdings Gross Profit Chart

Longevity Health Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Gross Profit
- - - 0.04

Longevity Health Holdings Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 0.02 0.02

Competitive Comparison of Longevity Health Holdings's Gross Profit

For the Household & Personal Products subindustry, Longevity Health Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longevity Health Holdings's Gross Profit Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Longevity Health Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Longevity Health Holdings's Gross Profit falls into.


;
;

Longevity Health Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Longevity Health Holdings's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.05 - 0.006
=0.04

Longevity Health Holdings's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.017 - 0.001
=0.02

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Longevity Health Holdings's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.02 / 0.017
=94.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Longevity Health Holdings  (NAS:XAGE) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Longevity Health Holdings had a gross margin of 94.12% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Longevity Health Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Longevity Health Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Longevity Health Holdings Business Description

Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Longevity Health Holdings Inc is a United States based bio-aesthetics company that utilizes the Secretome to support skin and hair health.
Executives
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036